To increase research, education, and treatment for cerebral cavernous malformations.
Summary
What This Bill Does
The bill provides findings Congress finds as follows: Cerebral cavernous malformations (referred to in this section as CCM), also known as cavernous angioma, or cavernoma, is a devastating blood vessel disease characterized, creates expansion and coordination of activities of national institutes of health with respect to cerebral cavernous malformations research Part B of title IV of the Public Health Service Act (42 U.S.C, and creates cerebral cavernous malformations research activities The Director of NIH, in coordination with the directors of the National Institute of Neurological Disorders and Stroke, the National Center for Advancing. It relies on appropriations, reporting requirements, grants, and compliance mandates. The main policy areas are Education, Healthcare, Environment, and Science & Space.
Who Benefits and How
Patients and health care consumers affected by the bill could gain revenue opportunities, Educational institutions and students affected by the bill could gain revenue opportunities, and Environmental and public health interests affected by the bill could face lower compliance burdens.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties.
Key Provisions
- Provides findings Congress finds as follows: Cerebral cavernous malformations (referred to in this section as CCM), also known as cavernous angioma, or cavernoma, is a devastating blood vessel disease characterized...
- Creates expansion and coordination of activities of national institutes of health with respect to cerebral cavernous malformations research Part B of title IV of the Public Health Service Act (42 U.S.C.
- Creates cerebral cavernous malformations research activities The Director of NIH, in coordination with the directors of the National Institute of Neurological Disorders and Stroke, the National Center for Advancing...
- Creates centers for disease control and prevention cerebral cavernous malformations surveillance and research programs Part B of title III of the Public Health Service Act (42 U.S.C.
- Creates cerebral cavernous malformations surveillance and research programs The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may award grants in such sums as may be necessary...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill provides findings Congress finds as follows: Cerebral cavernous malformations (referred to in this section as CCM), also known as cavernous angioma, or cavernoma, is a devastating blood vessel disease characterized, creates expansion and coordination of activities of national institutes of health with respect to cerebral cavernous malformations research Part B of title IV of the Public Health Service Act (42 U.S.C, and creates cerebral cavernous malformations research activities The Director of NIH, in coordination with the directors of the National Institute of Neurological Disorders and Stroke, the National Center for Advancing.
Key Policy Areas
Education, Healthcare, Environment, Science & Space
Primary Purpose
The bill provides findings Congress finds as follows: Cerebral cavernous malformations (referred to in this section as CCM), also known as cavernous angioma, or cavernoma, is a devastating blood vessel disease characterized, creates expansion and coordination of activities of national institutes of health with respect to cerebral cavernous malformations research Part B of title IV of the Public Health Service Act (42 U.S.C, and creates cerebral cavernous malformations research activities The Director of NIH, in coordination with the directors of the National Institute of Neurological Disorders and Stroke, the National Center for Advancing.
Policy Domains
Whole bill
Identified Gains
- Patients and health care consumers affected by the bill
- Educational institutions and students affected by the bill
- Environmental and public health interests affected by the bill
- Researchers and scientific institutions affected by the bill
- Energy producers and energy supply-chain firms affected by the bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
Sponsors
Legislative Progress
IntroducedMr. Luján (for himself and Mr. Heinrich) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology